

# **SAVEBUX ENTERPRISE PRIVATE LIMITED**

**[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]**

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060. CIN: U24100GJ2017PTC099389,  
Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

---

## **NOTICE**

**NOTICE** is hereby given that the 2<sup>nd</sup> Annual General Meeting of the members of **Savebux Enterprise Private Limited** [Formally Known as Savebux Finance & Investment Private Limited] will be held on Thursday, August 29, 2019 at 11:00 a.m. at the Registered Office of the Company at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060 to transact the following businesses:

### **ORDINARY BUSINESS:**

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year Ended on March 31, 2019 including the Balance Sheet as at March 31, 2019, the Statement of Profit and Loss and Cash flow for the Year Ended on that date along with reports of the Board of Directors and the Auditors thereon.

**By Order Of the Board  
For Savebux Enterprise Private Limited**

**Ahmedabad, May 29, 2019**

### **Registered Office:**

"LINCOLN HOUSE",  
Behind Satyam Complex,  
Science City Road, Sola,  
Ahmedabad-380060.

**Munjal M. Patel**  
Director  
DIN: 02319308

### **NOTES:**

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT ALL MEETINGS IS ALSO ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND ON BEHALF OF HIM AND THAT A PROXY NEED NOT BE A MEMBER OF THE COMPANY.
2. Proxies in order to be effective should be duly completed stamped and signed and must be deposited at the Registered Office of the Company not less than 48 hours before the conclusion of the meeting.
3. Members are requested to notify immediately any change in their address to the Company at its Registered Office.
4. Members desiring any information as regards accounts are requested to write to the company at least 7 days before the meeting to enable the management to keep the information ready

# **SAVEBUX ENTERPRISE PRIVATE LIMITED**

**[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]**

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola,  
Ahmedabad-380060. CIN: U24100GJ2017PTC099389,  
Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

---

## **DIRECTORS' REPORT**

To  
**The members,  
Savebux Enterprise Private Limited**

Your Directors are pleased to present the Second Annual Report on the business and operations of Savebux Enterprise Private Limited together with Audited Financial Statements for the Financial Year Ended on March 31, 2019.

### **FINANCIAL PERFORMANCE/ STATE OF COMPANY AFFAIRS:-**

(Amt. In Lakhs)

<b>Particulars</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
Revenue from Operations	-	-
Other income	12.22	3.27
Profit before Depreciation and Taxation	3.66	3.26
less: Depreciation	-	-
Profit before Taxation	3.66	3.26
Less: Tax Expenses	1.02	0.84
Profit After Tax for the year	2.64	2.42

### **DIVIDEND AND TRANSFER TO RESERVES:-**

In order to conserve the resources, your directors do not recommend any payment of dividend for the year under review. Further the Company has not transferred any amount to reserves during the year.

### **MATERIAL CHANGES AFFECTING FINANCIAL POSITION OF THE COMPANY:-**

No material changes or commitments, affecting the financial position of the Company have occurred between the end of the financial year of the company under review and the date of the Board's Report.

### **CHANGE IN THE NATURE OF BUSINESS:-**

The Company changed its object as the application made by the Company for obtaining registration as NBFC Company is rejected by Reserve Bank of India. As the Company cannot carry out NBFI activities without obtaining registration from Reserve Bank of India, the Board of Directors of the Company thought it prudent to change the object of the Company. Hence, the Board of Directors of the Company considered it desirable and necessary to change the object of the Company and company have changed its object from NBFC Activities to Trading of Pharmaceuticals Products.

# **SAVEBUX ENTERPRISE PRIVATE LIMITED**

**[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]**

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060. CIN: U24100GJ2017PTC099389, Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

---

## **SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES:**

The Company have not any Subsidiary, Joint venture or Associate Company. Further, the Company is Wholly Owned Subsidiary Company of "Lincoln Pharmaceuticals Limited".

## **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO:-**

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated hereunder:-

### **a) CONSERVATION OF ENERGY:**

#### **A. The steps taken or impact on conservation of energy:**

The Company has taken measures and applied strict control system to monitor day to day power consumption, to endeavor to ensure the optimal use of energy with minimum extent possible wastage as far as possible. The day to day consumption is monitored and various ways and means are adopted to reduce the power consumption in an effort to save energy.

#### **B. The steps taken by the Company for utilizing alternate sources of energy:**

Company has not taken any step for utilizing alternate sources of energy.

#### **C. The Capital investment on energy conservation equipments:**

Company has not made any capital investment on energy conservation equipments.

### **b) TECHNOLOGY ABSORPTION:**

Company have not imported any technology and hence there is nothing to be reported here.

### **c) FOREIGN EXCHANGE EARNINGS AND OUT GO:**

- i. CIF Value of Import: Nil
- ii. Expenditure in Foreign Currency: Nil
- iii. Earning: Nil

# **SAVEBUX ENTERPRISE PRIVATE LIMITED**

**[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]**

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola,  
Ahmedabad-380060. CIN: U24100GJ2017PTC099389,  
Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

---

## **CORPORATE SOCIAL RESPONSIBILITY:-**

The Company has not fall under the criteria as specified under Section 135 of the Companies Act, 2013, thus it is not applicable.

## **LOANS FROM DIRECTOR/RELATIVE OF DIRECTOR:**

The balances of monies accepted by the Company from Directors / relatives of Directors at the beginning of the year were Nil and at the close of year was Nil.

## **LOANS, GUARANTEES & INVESTMENTS U/S 186:-**

There were no loans, guarantees or investments made by the Company under Section 186 of the Companies Act, 2013 during the year under review and hence the said provision is not applicable.

## **CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:-**

There were no related party transactions made by the Company during the year under review.

## **INTERNAL FINANCIAL CONTROL SYSTEM:-**

The Company has an Internal Financial Control System, commensurate with the size, scale and complexity of its operations. The scope and authority of the Internal Financial Control function is well defined.

## **PARTICULARS OF EMPLOYEES:-**

During the year under review, there are no employees drawing remuneration which is in excess of the limit as prescribed under Section 197 of the Companies Act, 2013 read with rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

## **INDUSTRIAL RELATIONS:-**

The Directors are pleased to report that the relations between the employees and the management continued to remain cordial during the year under review.

## **DEPOSITS:-**

The Company has not accepted any deposit within the meaning of Section 73 of the Companies Act, 2013 during the year under review.

# **SAVEBUX ENTERPRISE PRIVATE LIMITED**

**[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]**

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola,  
Ahmedabad-380060. CIN: U24100GJ2017PTC099389,  
Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

---

## **DIRECTORS:-**

During the period under Review, there is no change in board of directors of the Company.

## **NUMBER OF BOARD MEETINGS OF THE BOARD:-**

During the year under review, the Board of Directors duly met 4 times and the details of attendance of directors / members are as follows:

During the year under review, the Board met 4 (four) times as on 25<sup>th</sup> May, 2018, 14<sup>th</sup> August, 2018, 13<sup>th</sup> November, 2018 and 5<sup>th</sup> February, 2019 Proper notices were given and the proceedings were properly recorded and signed in the Minutes book as required by the Articles of Association of the Company and the Companies Act, 2013.

## **DIRECTORS' RESPONSIBILITY STATEMENT:-**

It is hereby stated that:

- a) In the preparation of annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures.
- b) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the Profit of the Company for that period.
- c) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The Directors have prepared the annual accounts on going concern basis.
- e) The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

## **STATUTORY AUDITORS AND THEIR OBSERVATION:**

M/s. K. P. Sompura & Company, Chartered Accountants [FRN: 131641W] were appointed as Statutory Auditors, for a term of five years to hold office till the conclusion of the Annual general Meeting to be held for the Financial Year Ending on March 31, 2023.

In view of the amended provisions of Section 139 by The Companies (Amendment) Act, 2017, the appointment of auditors is not required to be ratified Every Year at the Annual General Meeting by the members of the Company and hence present Statutory

# **SAVEBUX ENTERPRISE PRIVATE LIMITED**

**[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]**

**Regd. Office:** "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola,  
Ahmedabad-380060. **CIN:** U24100GJ2017PTC099389,  
**Email:** cs@lincolnpharma.com, **Ph. No.:** +91-79-4107-8000.

---

Auditors of the Company will continue to act as Statutory Auditor till the expiry of their present term.

The Auditors' Report to the members for the year under review does not contain any qualification.

## **MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS:-**

No significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

## **ANNUAL RETURN:-**

Extract of the Annual Return for the financial year ended under review in the prescribed form MGT - 9, pursuant to provisions of Section 92(3) of the Companies Act, 2013 is annexed to this report as **Annexure A**.

## **ACKNOWLEDGEMENT:**

Your Directors are thankful to regulatory and Government authorities, bankers and clients of the Company.

**FOR AND ON BEHALF OF BOARD  
FOR SAVEBUX ENTERPRISE PRIVATE LIMITED**

**PLACE: AHMEDABAD  
DATE: MAY 29, 2019**

\_\_\_\_\_  
**MAHENDRA G. PATEL  
DIRECTOR  
DIN: 00104780**

\_\_\_\_\_  
**MUNJAL M. PATEL  
DIRECTOR  
DIN: 02319308**

# **SAVEBUX ENTERPRISE PRIVATE LIMITED**

**[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]**

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060. CIN: U24100GJ2017PTC099389, Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

## **ANNEXURE 'A'**

### **FORM NO. MGT - 9**

### **EXTRACT OF ANNUAL RETURN**

**As on the Financial Year ended on March 31, 2019**

[Pursuant to Section 92(3) of the Companies Act, 2013, and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

#### **1. REGISTRATION AND OTHER DETAILS**

<b>CIN</b>	U24100GJ2017PTC099389
<b>Registration Date:</b>	09/10/2017
<b>Name of the Company:</b>	Savebux Enterprises Private Limited
<b>Category / Sub-category of the Company:</b>	<ul style="list-style-type: none"><li>• Company Limited By Share</li><li>• Indian Non- Government Company</li></ul>
<b>Registered Office Details:</b>	"LINCON HOUSE", Behind Satyam Complex, Science City Road,Sola, Ahmedabad-380060.
<b>Whether Listed Company:</b>	No
<b>Name, Address and contact details of RTI, if any:</b>	N.A.

#### **2. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY**

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

<b>SR. No.</b>	<b>Name and Description of main products</b>	<b>NIC Code of the Product/ service</b>	<b>% to total turnover of the company</b>
NIL			

#### **3. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES: N.A.**

<b>SN</b>	<b>Name and Address of the Company</b>	<b>CIN</b>	<b>Holding / Subsidiary</b>	<b>% of shares held</b>	<b>Applicable Section</b>
1.	Lincoln Pharmaceuticals Limited	L24230GJ1995PLC024288	Holding	100	2 (46)





# SAVEBUX ENTERPRISE PRIVATE LIMITED

[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060. CIN: U24100GJ2017PTC099389,

Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

holding nominal share capital in excess of Rs 1 lakh									
c) Other (specify)	---	---	---	---	---	---	---	---	---
<b>Sub-Total (B) (2):-</b>	---	---	---	---	---	---	---	---	---
<b>Total Public Shareholding (B) = (B) (1) + (B) (2)</b>	---	---	---	---	---	---	---	---	---
C. Shares held by Custodian for GDRs & ADRs	---	---	---	---	---	---	---	---	---
<b>Grand Total (A+B+C)</b>	<b>0</b>	<b>20,00,000</b>	<b>20,00,000</b>	<b>100</b>	<b>0</b>	<b>20,00,000</b>	<b>20,00,000</b>	<b>100</b>	<b>---</b>

## ii. Shareholding of Promoters

SN	Shareholders' Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of Total Shares of the Company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of Total Shares of the Company	% of Shares Pledged / encumbered to total shares	
1.	Lincoln Pharmaceuticals Limited	19,99,998	99.99999	----	19,99,998	99.99999	----	----
2.	Mahendra G. Patel (Nominee of Lincoln Pharmaceuticals Ltd)	1	0.00005	----	1	0.00005	----	----
4.	Munjal M. Patel (Nominee of Lincoln Pharmaceuticals Ltd)	1	0.00005	----	1	0.00005	----	----
<b>TOTAL</b>		<b>20,00,000</b>	<b>100</b>	<b>----</b>	<b>20,00,000</b>	<b>100</b>	<b>----</b>	<b>----</b>

## iii. Change in Promoters' Shareholding (No Change in Promoter's Shareholding)

## iv. Shareholding Pattern of top ten Shareholders

(Other than Directors, Promoters and Holders of GDRs and ADRs):N.A.

## v. Shareholding of Directors & KMP:

SN		Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of total shares of the company	No. of Shares	% of total shares of the company
<b>1.</b>	<b>Mahendra G. Patel</b>				
	At the Beginning of the Year	---	---	---	---
	Date wise Increase / Decrease Shareholding	<b>None</b>			
	At the End of the Year	---	---	---	---
<b>2.</b>	<b>Munjal M. Patel</b>				
	At the Beginning of the Year	---	---	---	---
	Date wise Increase / Decrease Shareholding	<b>None</b>			
	At the End of the Year	---	---	---	---

# SAVEBUX ENTERPRISE PRIVATE LIMITED

[Formally known as SAVEBUX FINANCE & INVESTMENT PRIVATE LIMITED]

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola,  
Ahmedabad-380060. CIN: U24100GJ2017PTC099389,  
Email: cs@lincolnpharma.com, Ph. No.: +91-79-4107-8000.

## 5. INDEBTEDNESS:

**Indebtedness of the Company including interest outstanding/accrued but not due for payment**

(Amt. in Rs.)

	Secured Loans Excluding Deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the Beginning of the Financial Year				
i. Principal Amount	----	----	----	----
ii. Interest due but not paid	----	----	----	----
iii. Interest accrued but not due	----	----	----	----
<b>Total (i+ ii+ iii)</b>	----	----	----	----
Change in Indebtedness during the Financial Year				
i. Addition	----	----	----	----
ii. Reduction	----	----	----	----
<b>Net Change</b>	----	----	----	----
Indebtedness at the End of the Financial Year				
i. Principal Amount	----	----	----	----
ii. Interest due but not paid	----	----	----	----
iii. Interest accrued but not due	----	----	----	----
<b>Total (i+ ii+ iii)</b>	----	----	----	----

## 6. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL.

**A. Remuneration to Managing Director, Whole-Time Directors and/or Manager: N.A.**

**B. Remuneration to other Directors: N.A.**

**C. Remuneration to KMP other than MD/Manager/WTD: N.A.**

## 7. PENALTIES/PUNISHMENT/COMPOUNDING OF OFFENCES:

There were no penalties/Punishment/Compounding of Offences for the year ended on March 31, 2019.

**FOR AND ON BEHALF OF BOARD  
FOR SAVEBUX ENTERPRISES PRIVATE LIMITED**

**PLACE: AHMEDABAD  
DATE: MAY 29, 2019**

**MAHENDRA G. PATEL  
DIRECTOR  
DIN: 00104780**

**MUNJAL M. PATEL  
DIRECTOR  
DIN: 02319308**

Titanium City Center, Office No. H-111, 1st Floor, Nr. Sachin Tower, 100 Ft. Anand Nagar  
Road, Satellite, Ahmedabad-380015. Ph. No.: 079-40062332, Mob. +91-9825304497,  
E-Mail: kpsompura1356@gmail.com

---

**INDEPENDENT AUDITOR'S REPORT**

To  
The members of  
**Savebux Enterprise Private Limited**  
Ahmedabad

**Report on the Audit of the Financial Statements**

**Opinion**

1. We have audited the accompanying financial statements of Savebux Enterprise Private Limited [Formerly known as: Savebux Finance & Investment Private Limited] ("the company") which comprise the Balance Sheet as at **31<sup>st</sup> March, 2019**, and the Statement of Profit and Loss, the Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone financial statements give the information required by the Companies Act, 2013 (the 'Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under Section 133 of the Act, of the state of affairs of the Company as at 31 March 2019, and its profit, total comprehensive income, its cash flows and the changes in equity for the year ended on that date.

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Titanium City Center, Office No. H-111, 1st Floor, Nr. Sachin Tower, 100 Ft. Anand Nagar Road, Satellite, Ahmedabad-380015. Ph. No.: 079-40062332, Mob. +91-9825304497,  
E-Mail: kpsompura1356@gmail.com

---

#### **Key Audit Matters**

4. Key audit matters are those matters that, in our professional judgment were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole and in forming our opinion thereon and we do not provide a separate opinion on these matters.
5. Key audit matter identified in our audit is on recoverability assessment of trade receivables as follows:

<b>Key audit matter</b>	<b>How our audit addressed the key audit matter</b>
<b>Measurement of Advance for Goods</b>	
The company had given Rs. 2,13,50,000/- as an advance for goods in normal course of business.	<ul style="list-style-type: none"><li>• Obtained a list of advance for goods</li><li>• We obtained closing balance confirmations;</li></ul>

#### **Information other than the Standalone Financial Statements and Auditors' Report thereon**

6. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and as may be legally advised.

#### **Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements**

7. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally

Titanium City Center, Office No. H-111, 1st Floor, Nr. Sachin Tower, 100 Ft. Anand Nagar Road, Satellite, Ahmedabad-380015. Ph. No.: 079-40062332, Mob. +91-9825304497,  
E-Mail: kpsompura1356@gmail.com

---

accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

8. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
9. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditors' Responsibilities for the Audit of the Standalone Financial Statements**

10. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
11. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis of opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for our resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Titanium City Center, Office No. H-111, 1st Floor, Nr. Sachin Tower, 100 Ft. Anand Nagar Road, Satellite, Ahmedabad-380015. Ph. No.: 079-40062332, Mob. +91-9825304497,  
E-Mail: kpsompura1356@gmail.com

---

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial control system in place and the operating effectiveness of such controls.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
  - Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 12.** We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- 13.** We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable, and where applicable, related safeguards.
- 14.** From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

**CA KISHOR P. SOMPURA**  
**B.COM, A.C.A.**  
**MEMBERSHIP NO.: 045155**

**K. P. SOMPURA & COMPANY**  
**CHARTERED ACCOUNTANTS**  
**FRN NO.: 131641W**

Titanium City Center, Office No. H-111, 1st Floor, Nr. Sachin Tower, 100 Ft. Anand Nagar  
Road, Satellite, Ahmedabad-380015. Ph. No.: 079-40062332, Mob. +91-9825304497,  
E-Mail: kpsompura1356@gmail.com

---

### **Report on Other Legal and Regulatory Requirements**

We report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b) In our opinion proper books of account as required by law have been kept by the LLP so far as appears from our examination of those books.
- c) The Balance Sheet and the statement profit & loss dealt with by this Report is in agreement with the books of account.
- d) In our opinion the Balance Sheet and the statement of profit & loss comply with the Accounting Standards to the extent applicable.

**For K. P. Sompura & Co.**  
**Chartered Accountants**  
**(FRN: 131641W)**

**K. P. Sompura**  
**Proprietor**  
**(Membership No. 045155)**

**Place: Ahmedabad**  
**Date: 29/05/2019**

**Savebux Enterprise Private Limited**

Formerly Known as : Savebux Finance Investment Private Limited

Balance Sheet as at March 31, 2019				
Particulars		Note No.	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
A	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	(a) Property, Plant and Equipment		Nil	Nil
	(b) Financial Assets			
	(i) Investments		Nil	Nil
	(ii) Loans		Nil	Nil
	(c) Other non-current assets		Nil	Nil
	<b>Total Non - Current Assets</b>		<b>Nil</b>	<b>Nil</b>
2	<b>Current assets</b>			
	(a) Inventories		Nil	Nil
	(b) Financial Assets			
	(i) Investments		Nil	Nil
	(ii) Trade receivables		Nil	Nil
	(iii) Cash and cash equivalents	5	83,615	8,761
	(iv) Other Bank balances	6	Nil	2,02,81,248
	(v) Loans		Nil	Nil
	(vi) Other Financial assets	7	Nil	46,564
	(c) Current Tax Assets (Net)	8	1,74,805	Nil
	(d) Other current assets	9	2,13,50,000	Nil
	<b>Total Current Assets</b>		<b>2,16,08,420</b>	<b>2,03,36,573</b>
	<b>Total Assets (1+2)</b>		<b>2,16,08,420</b>	<b>2,03,36,573</b>
B	<b>EQUITY AND LIABILITIES</b>			
1	<b>Equity</b>			
	(a) Equity share capital	10	2,00,00,000	2,00,00,000
	(b) Other Equity	11	5,06,341	2,42,480
	<b>Total equity</b>		<b>2,05,06,341</b>	<b>2,02,42,480</b>
2	<b>LIABILITIES</b>			
	<b>Non-current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		Nil	Nil
	(iii) Other financial liabilities		Nil	Nil
	(b) Deferred tax liabilities (Net)		Nil	Nil
	<b>Total Non - Current Liabilities</b>		<b>Nil</b>	<b>Nil</b>
3	<b>Current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		Nil	Nil
	(ii) Trade payables	12	8,30,000	Nil
	(iii) Other financial liabilities	13	1,70,000	10,000
	(b) Other current liabilities		Nil	Nil
	(c) Current Tax Liabilities (Net)	14	1,02,079	84,093
	<b>Total Current Liabilities</b>		<b>11,02,079</b>	<b>94,093</b>
	<b>Total Equity and Liabilities (1+2+3)</b>		<b>2,16,08,420</b>	<b>2,03,36,573</b>
	<b>Summary of Significant Accounting Policies</b>	4		
<p>As per our report of even date attached herewith.</p> <p>For, K. P. Sompura &amp; Co. Chartered Accountants (Firm Regd. No. 131641W)</p> <p>(K. P. Sompura) Proprietor (M. No. 045155) Place: Ahmedabad Date: 29/05/2019</p> <p>For, Savebux Enterprise Private Limited [Formally known as Savebux Finance &amp; Investment Private Limited]</p> <p>Munjal M Patel (DIN : 02319308) Director Place: Ahmedabad Date: 29/05/2019</p> <p>Mahendra G Patel (DIN : 00104706) Director</p>				



**Savebux Enterprise Private Limited**  
**Formally Known as : Savebux Finance Investment Private Ltd.**

Statement of Profit and Loss for the year ended March 31, 2019			
Particulars	Note No.	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
<b>Continuing Operations</b>			
I Revenue from operations	15	12,21,664	3,27,812
II Other Income		Nil	Nil
<b>III Total Income (I + II)</b>		<b>12,21,664</b>	<b>3,27,812</b>
<b>IV EXPENSES</b>			
(a) Cost of materials consumed		Nil	Nil
(b) Purchases of stock-in-trade		Nil	Nil
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress		Nil	Nil
(d) Excise duty		Nil	Nil
(e) Employee benefit expense	16	4,70,000	Nil
(f) Finance costs	17	2,224	1,239
(g) Depreciation and amortisation expense		Nil	Nil
(h) Other expenses	18	3,83,500	Nil
<b>Total Expenses</b>		<b>8,55,724</b>	<b>1,239</b>
<b>V Profit/(loss) before tax (III- IV)</b>		<b>3,65,940</b>	<b>3,26,573</b>
<b>VI Tax Expense</b>			
(1) Current tax	19	1,02,079	84,093
(2) Deferred tax			
<b>Total tax expense</b>		<b>1,02,079</b>	<b>84,093</b>
<b>VII Profit/(loss) after tax from continuing</b>		<b>2,63,861</b>	<b>2,42,480</b>
<b>VIII Other Comprehensive Income</b>			
Items that will not be reclassified to Statement of profit and loss			
a) Remeasurements of the defined benefit plans		Nil	Nil
b) Income tax relating to items (a) above		Nil	Nil
<b>IX Total Other Comprehensive Income</b>		<b>Nil</b>	<b>Nil</b>
<b>X Total comprehensive income for the period (VIII+IX)</b>		<b>2,63,861</b>	<b>2,42,480</b>
<b>XI Basic &amp; diluted earnings per share of face value of Rs.10 each Fully Paid up</b>			
(1) Basic	20	0.13	0.12
(2) Diluted	20	0.13	0.12

As per our report of even date attached herewith.

For, K. P. Sompura & Co.  
Chartered Accountants  
(Firm Regd. No. 131641W)

For, Savebux Enterprise Private Limited  
[Formally known as Savebux Finance & Investment Private Limited]

(K. P. Sompura)  
Proprietor  
(M. No. 045155)  
Place: Ahmedabad  
Date: 29/05/2019

Munjal M Patel  
(DIN : 02319308)  
Director  
Place : Ahmedabad  
Date: 29/05/2019

Mahendra G Patel  
(DIN : 00104706)  
Director

# Savebux Enterprise Private Limited

Formally Known as : Savebux Finance Investment Private Ltd.

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2019		
Particulars	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
<b>Cash flow from operating activities</b>		
Profit before tax	3,65,940	3,26,573
<b>Adjustments for :</b>		
Finance costs	Nil	Nil
<b>Operating profit before working capital changes</b>	<b>3,65,940</b>	<b>3,26,573</b>
<b>Changes in operating assets and liabilities:</b>		
(Increase)/Decrease in loans (current financial asset)	46,564	(46,564)
(Increase)/Decrease in other current assets	(2,13,50,000)	Nil
(Increase)/Decrease in other bank balance	2,02,81,248	(2,02,81,248)
Increase/(Decrease) in trade payable	8,30,000	Nil
Increase/(Decrease) in other current financial liabilities	1,60,000	10,000
<b>Cash flow generated from operations</b>	<b>(32,188)</b>	<b>(2,03,17,812)</b>
Direct taxes paid (net)	(2,58,898)	Nil
<b>NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES (A)</b>	<b>74,854</b>	<b>(1,99,91,239)</b>
<b>Cash flows from investing activities</b>		
Changes in Equity Share Capital	Nil	2,00,00,000
<b>NET CASH FLOW FROM / (USED IN) IN INVESTING ACTIVITIES (B)</b>	<b>Nil</b>	<b>2,00,00,000</b>
<b>Cash flows from financing activities</b>		
Finance costs paid	Nil	Nil
Repayment of short-term borrowings	Nil	Nil
Repayment of long-term borrowings	Nil	Nil
<b>NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES (C)</b>	<b>Nil</b>	<b>Nil</b>
<b>NET INCREASED / (DECREASED) IN CASH AND CASH EQUIVALENTS (A + B + C)</b>	<b>74,854</b>	<b>8,761</b>
Cash and cash equivalents at the beginning of the year	8,761	Nil
<b>Cash and cash equivalents at the end of the year</b>	<b>83,615</b>	<b>8,761</b>
<b>Notes:</b>		
(i). Components of cash and cash equivalents at each balance sheet:		
	Year Ended March 31, 2019 Rs.	Year Ended March 31, 2018 Rs.
Particulars		
Cash on hand	-	-
Balances with Bank - In Current Account	83,615	8,761
<b>Total Cash and cash equivalents</b>	<b>83,615</b>	<b>8,761</b>
(ii). The above cash flow statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard - 7 Cash Flow Statements specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.		
<b>See accompanying notes forming part of the Financial Statements</b>		
<b>As per our report of even date attached herewith.</b>		
For, K. P. Sompura & Co. Chartered Accountants (Firm Regd. No. 131641W)	For, Savebux Enterprise Private Limited [Formally known as Savebux Finance & Investment Private Limited]	
(K. P. Sompura) Proprietor (M. No. 045155) Place: Ahmedabad Date: 29/05/2019	Munjali M Patel (DIN : 02319308) Director Place: Ahmedabad Date: 29/05/2019	Mahendra G Patel (DIN : 00104706) Director

**Statement of Changes in Equity for the year ended on March 31, 2019**

**Equity Share Capital**

Particulars	Note No.	Amount Rs.
Balance as on 1st April, 2017	10	-
Changes during the year		2,00,00,000
Balance as on 31st March, 2018	10	2,00,00,000
Changes during the year		Nil
Balance as on 31st March, 2019	10	2,00,00,000

**Other Equity**

Particulars	Note No.	Reserves and Surplus			Total
		Retained Earnings		General Reserve	
		Profit and Loss	Other Comprehensive Income		
Balance as at 1st April, 2017	11	Nil	Nil	Nil	Nil
Profit for the year		2,42,480	Nil	Nil	2,42,480
Balance as at 31st March, 2018	11	2,42,480	Nil	Nil	2,42,480
Profit for the year		2,63,861	Nil	Nil	2,63,861
Balance as at 31st March, 2019	11	5,06,341	Nil	Nil	5,06,341

As per our report of even date attached herewith.  
 For, K. P. Sompura & Co.  
 Chartered Accountants  
 (Firm Regd. No. 131641W)

For, Savebux Enterprise Private Limited  
 [Formally known as Savebux Finance & Investment Private Limited]

(K. P. Sompura)  
 Proprietor  
 (M. No. 045155)  
 Place: Ahmedabad  
 Date: 29/05/2019

Munjal M Patel  
 (DIN : 02319308)  
 Director  
 Place : Ahmedabad  
 Date: 29/05/2019

Mahendra G Patel  
 (DIN : 00104706)  
 Director

## **Notes to financial statement for the Year Ended March 31, 2019**

### **1. Corporate Information**

The Savebux Enterprise Private Limited [Formerly known as Savebux Finance & Investment Private Ltd] ("the company"), is incorporated on October 9, 2017 under the provisions of the Companies Act 2013, having its registered office in the Ahmedabad, Gujarat.

The financial statements are approved for issue by the Company's Board of Directors on May 29, 2019.

### **2. Statement of Compliance**

The financial statements have been prepared in accordance with Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended read with Section 133 of the Companies Act, 2013, As it is the Wholly-on Subsidiary company of the Lincoln Pharmaceuticals Ltd ("the Holding Company") who is under the frame of IND AS.

The current financial statements comprising of Balance Sheet, Statement of Profit and Loss, Statement of Changes in Equity and Statement of Cash Flows as at March 31, 2019 have been prepared in accordance with Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. These are the Company's first Ind AS financial statements.

### **3. Basis of preparation**

The financial statements have been prepared on accrual basis of accounting under historical cost convention in accordance with generally accepted accounting principles in India and the relevant provisions of the Companies Act, 2013 including Indian Accounting Standards notified there under.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2, or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;

Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and

Level 3 inputs are unobservable inputs for the asset or liability

### **4. Summary of significant accounting policies:**

#### **i. Use of estimates:**

The preparation of these financial statements in conformity with the recognition and measurement principles of Ind AS requires the management of the Company to make estimates and assumptions that affect the reported balances of assets and liabilities, disclosures relating to contingent liabilities as at the date of the financial statements and the reported amounts of income and expense for the periods

presented. The estimates and assumptions used in the accompanying financial statements are based upon management's evaluation of relevant facts and circumstances as at the date of the financial statements. Management believes that the estimates used in the preparation of financial statements are prudent and reasonable. Actual results could differ from estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and future periods are affected.

Key source of estimation of uncertainty at the date of the financial statements, which may cause a material adjustment to the carrying amounts of assets and liabilities in coming financial years are specified here-in-after:

**Provisions and contingent liabilities:**

A Provisions recognized when the Company has a present obligation as a result of past event and it is probable than an outflow of resources will be required to settle the obligation, in respect of which the reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date, adjusted to reflect the current best estimates. Contingent liabilities are not recognized in the financial statements. A contingent asset is neither recognized nor disclosed in the Financial Statement.

**Other estimates:**

The preparation of financial statements involves estimates and assumptions that affect the reported amount of assets, liabilities, disclosure of contingent liabilities at the date of financial statements and the reported amount of revenues and expenses for the reporting period. Specifically, the Company estimates the probability of collection of accounts receivable by analyzing historical payment patterns, customer concentrations, customer credit-worthiness and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.

**ii. Revenue recognition:**

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are inclusive of excise duty and net of customers' return, trade discounts, rebates, value added taxes, goods & service taxes and any other claims in respect of sale.

**iii. Income Taxes:**

Income tax expense represents the sum of the tax currently payable and deferred tax.

**Current tax:**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

**Deferred tax:**

Deferred tax liability or asset is recognized for timing differences between the profits/losses offered for income taxes and profits/ losses as per the financial statements. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognized only to the extent there is a reasonable certainty that the assets can be realized in future; however where there is unabsorbed depreciation or carried

forward loss under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed as at each balance sheet date and written down or written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realized.

**iv. Cash Flow Statement:**

Cash flows are reported using the indirect method, whereby profit / (loss) before tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

**v. Operating Cycle:**

The Operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle. Accordingly, all assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in Ind AS 1- 'Presentation of Financial Statements' and Schedule III to the Companies Act, 2013.

**Notes to financial statement for the year ended March 31, 2019**

		As at March 31, 2019	As at March 31, 2018		
		Rs.	Rs.		
<b>5</b>	<b>Cash &amp; Cash Equivalents</b>				
	Cash on hand	Nil	Nil		
	Balances with Bank - In Current Account	83,615	8,761		
	<b>Total</b>	<b>83,615</b>	<b>8,761</b>		
<b>6</b>	<b>Other Bank Balance</b>				
	Margin Money Deposit	Nil	2,02,81,248		
	<b>Total</b>	<b>Nil</b>	<b>2,02,81,248</b>		
<b>7</b>	<b>Other Financial Assets</b>				
	Balances with Statutory Authorities	Nil	46,564		
	<b>Total</b>	<b>Nil</b>	<b>46,564</b>		
<b>8</b>	<b>Current Tax Assets (Net)</b>				
	Advance Income Tax	2,58,898	Nil		
	Less : Provision for Income	84,093	Nil		
	<b>Total</b>	<b>1,74,805</b>	<b>Nil</b>		
<b>9</b>	<b>Other Current Assets</b>				
	Advance for Goods	2,13,50,000	Nil		
	<b>Total</b>	<b>2,13,50,000</b>	<b>Nil</b>		
<b>10</b>	<b>Equity Share Capital</b>				
	[i] Authorised Share Capital: 20,00,000 (PY.20,00,000) Equity shares of Rs.10 each	2,00,00,000	2,00,00,000		
	[ii] Issued, Subscribed & Paid-up Capital : 20,00,000 (PY.20,00,000) Equity shares of Rs. 10 each fully paid				
	<b>Total</b>	<b>2,00,00,000</b>	<b>2,00,00,000</b>		
(a)	Reconciliation of the number of shares outstanding and the amount of share capital as at March 31, 2019 and , March 31, 2018 is set out below:-				
	<b>Particulars</b>	<b>As at March 31, 2019</b>		<b>As at March 31, 2018</b>	
		<b>No. of Shares</b>	<b>Amt (Rs.)</b>	<b>No. of Shares</b>	<b>Amt (Rs.)</b>
	Shares at the beginning	20,00,000	2,00,00,000	0	0
	Addition	Nil	Nil	20,00,000	2,00,00,000
	Deletion	Nil	Nil	Nil	Nil
	<b>Shares at the end</b>	<b>20,00,000</b>	<b>2,00,00,000</b>	<b>20,00,000</b>	<b>2,00,00,000</b>
(b)	The details of shares holding more than 5% shares is set out below:-				
	<b>Name of the Share holder</b>	<b>As at March 31, 2019</b>		<b>As at March 31, 2018</b>	
		<b>No. of Shares</b>	<b>% held</b>	<b>No. of Shares</b>	<b>% held</b>
	Lincoln Pharmaceuticals Limited	20,00,000	100.00%	20,00,000	100.00%

		As at March 31, 2019	As at March 31, 2018
		Rs.	Rs.
11	<b>Other Equity</b>		
a	<b>Retained Earnings</b>		
	<b>Profit and Loss:</b>		
	Balance as per last financial Statement	2,42,480	Nil
	Add : Profit for the year	2,63,861	2,42,480
	<b>Net Surplus in the statement of profit and loss (i)</b>	<b>5,06,341</b>	<b>2,42,480</b>
	<b>Other Comprehensive Income</b>		
	Balance as per last financial Statement	Nil	Nil
	Add: Remeasurement of Defined benefit plans (including deferred tax)	Nil	Nil
	Less : Deferred Tax Asset on above	Nil	Nil
	<b>Net Surplus in the statement of other comprehensive income(ii)</b>	<b>Nil</b>	<b>Nil</b>
	<b>Total Retained Earnings (i + ii)</b>	<b>5,06,341</b>	<b>2,42,480</b>
	<b>Total</b>		
<p><b>Retained earnings:</b> Retained earnings can be utilised by the company for distribution to its equity shareholders of the company. The amount that can be distributed by the Company as dividends to its equity shareholders is determined based on the requirements of the Companies Act, 2013. Thus, the amounts reported above are not distributable in entirety.</p>			
12	<b>Trade Payable</b>	As at March 31, 2019	As at March 31, 2018
		Rs.	Rs.
	Payable to Micro and Small Enterprise	Nil	Nil
	Payable to others	8,30,000	Nil
	<b>Total</b>	<b>Nil</b>	<b>Nil</b>
<p>Dues to Micro and Small enterprises have been determined to the extent such parties have been identified on the basis of the information collected by the Management. This has been relied upon by the Auditors. The disclosure in respect of the MSMED Act,2006 has been as under .:</p>			
<b>Due to Micro and Small Enterprise</b>			
Under the Micro, Small and Medium Enterprises Development Act, 2006, (MSMED) which came in to			
	<b>Particulars</b>	<b>As At 31/03/2019</b>	<b>As At 31/03/2018</b>
		Rs.	Rs
	a) The Principal amount remaining unpaid to Micro and Small enterprise supplier as at the year end	Nil	Nil
	b) Interest due thereon	Nil	Nil
	c) Amount of interest paid by the Company in terms of section 16 of MSMED Act	Nil	Nil
	d) Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED 2006	Nil	Nil
	e) Amount of interest accrued and remaining unpaid at the end of accounting year	Nil	Nil
	f) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance of a deductible expenditure under section 23 of Micro, Small and Medium Enterprise Development Act, 2006.	Nil	Nil



Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company and the same has been relied by the Auditor.

<b>13</b>	<b><u>Other Current Financial Liabilities</u></b>	<b>As at March 31, 2019 Rs.</b>	<b>As at March 31, 2018 Rs.</b>
	Other Current Financial Liabilities	1,70,000	10,000
	<b>Total</b>	<b>1,70,000</b>	<b>10,000</b>
<b>14</b>	<b><u>Current Tax Liabilities (Net)</u></b>	<b>As at March 31, 2019 Rs.</b>	<b>As at March 31, 2018 Rs.</b>
	Provision For Income tax	1,02,079	84,093
	<b>Total</b>	<b>1,02,079</b>	<b>84,093</b>
<b>15</b>	<b><u>Revenue from Operation</u></b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	<b>Other Operating Revenue:</b>		
	Interest Income on FDR	12,21,664	3,27,812
	<b>Total</b>	<b>12,21,664</b>	<b>3,27,812</b>
<b>(a)</b>	<b>Reconciliation of Revenue recognised in the statement of profit and loss with the Contracted price :-</b>		
	<b>Particulars</b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	Gross Revenue	Nil	Nil
	Less: Rebate & Discount etc	Nil	Nil
	<b>Revenue recognised from Contract with Customers</b>	<b>Nil</b>	<b>Nil</b>
<b>(b)</b>	<b>Reconciliation of Revenue from operation with Revenue from contracts with Customers :-</b>		
	<b>Particulars</b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	Revenue from operation	12,21,664	3,27,812
	Less: Interest Income on FDR	12,21,664	3,27,812
	<b>Revenue from contracts with Customers</b>	<b>Nil</b>	<b>Nil</b>
<b>16</b>	<b><u>Employee Benefit Expense</u></b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	Salary, Wages & Bonus	4,70,000	Nil
	<b>Total</b>	<b>4,70,000</b>	<b>Nil</b>
<b>17</b>	<b><u>Finance Costs</u></b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	Bank Charges	2,224	1,239
	<b>Total</b>	<b>2,224</b>	<b>1,239</b>

<b>18</b>	<b>Other Expense</b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	Audit Fees	10,000	Nil
	Office Expense	3,73,500	Nil
	<b>Total</b>	<b>3,83,500</b>	<b>Nil</b>
<b>19</b>	<b>Income tax recognised in profit or loss</b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	<b>Current tax:</b>		
	In respect of the current year	1,02,079	84,093
	In respect of the prior year	Nil	Nil
	<b>Sub-Total (i)</b>	<b>1,02,079</b>	<b>84,093</b>
	<b>Deffered tax:</b>		
	In respect of the current year	Nil	Nil
	<b>Sub-Total (ii)</b>	<b>Nil</b>	<b>Nil</b>
		<b>1,02,079</b>	<b>84,093</b>
	<b>Income tax reconciliation</b>	<b>For the year ended March 31, 2019 Rs.</b>	<b>For the year ended March 31, 2018 Rs.</b>
	<b>Particulars</b>		
	<b>Profit before tax</b>	3,65,940	3,26,573
	Tax expenses reported during the year	1,02,079	84,093
	Income tax expenses calculated - 25.75%	1,02,079	84,093
	<b>Difference</b>	<b>Nil</b>	<b>Nil</b>
<b>As per our report of even date attached herewith.</b>		<b>For, Savebux Enterprise Private Limited</b>	
<b>For, K. P. Sompura &amp; Co.</b>		[Formally known as Savebux Finance & Investment Private Limited]	
<b>Chartered Accountants</b>			
<b>(Firm Regd. No. 131641W)</b>			
<b>(K. P. Sompura)</b>	<b>Munjal M Patel</b>	<b>Mahendra G Patel</b>	
<b>Proprietor</b>	<b>(DIN : 02319308)</b>	<b>(DIN : 00104706)</b>	
<b>(M. No. 045155)</b>	<b>Director</b>	<b>Director</b>	
<b>Place: Ahmedabad</b>	<b>Place : Ahmedabad</b>		
<b>Date: 29/05/2019</b>	<b>Date: 29/05/2019</b>		

**20 Earnings Per Share (EPS)**

Particulars	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
Net Profit / (Loss) for calculation of basic / diluted EPS	2,63,861	2,42,480
Weighted Average Number of Equity Shares in calculating Basic and Diluted EPS	20,00,000	20,00,000
Basic and Diluted Earnings/(Loss) Per Share	0.13	0.12
Nominal Value of Equity Shares	10	10

**A. Reconciliation on Amount of EPS**

Particulars	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
<b>(a) Basic earnings per share</b>		
From continuing operations attributable to the equity holders of the company	0.13	0.12
<b>Total basic earnings per share attributable to the equity holders of the company</b>	0.13	0.12
<b>(b) Diluted earnings per share</b>		
From continuing operations attributable to the equity holders of the company	0.13	0.12
<b>Total diluted earnings per share attributable to the equity holders of the company</b>	0.13	0.12

**B. Reconciliations of earnings used in calculating earnings per share**

Particulars	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
<b>(a) Basic earnings per share</b>		
Profit attributable to the equity holders of the company used in calculating basic earnings per share:		
From continuing operations	2,63,861	2,42,480
<b>(b) Diluted earnings per share</b>		
Profit from continuing operations attributable to the equity holders of the company:		
Profit attributable to the equity holders of the company used in calculating diluted earnings per share	2,63,861	2,42,480

**C. Weighted average number of shares used as the denominator**

Particulars	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
<b>(a) Basic earnings per share</b>		
Weighted average number of equity shares used as the denominator in calculating basic earnings per share	20,00,000	20,00,000
<b>(b) Diluted earnings per share</b>		
Weighted average number of equity shares and potential equity shares used as the denominator in calculating diluted earnings per share	20,00,000	20,00,000

**D. Increase / decrease in EPS due to retrospective restatement of prior period error**

Particulars	As at March 31, 2019 Rs.	As at March 31, 2018 Rs.
(a) Basic earnings per share	Nil	Nil
(b) Diluted earnings per share	Nil	Nil

**21 Related Parties Disclosures**

<b>(i) List of related parties:</b>	
Name of related party	Nature of relationship
Lincoln Pharmaceuticals Limited	Holding Company
Lincoln Parenteral Limited	Another Subsidiary of Holding Company
<b>Key Managerial Personnel:</b>	
Munjaj M Patel	Key Managerial person
Mahendra G Patel	Key Managerial person

<b>(ii) Transactions during the period and balances outstanding with related parties are as under:</b>			
Transactions with related parties during the year:			
Name of related party	Nature of Transaction	Year ended March 31, 2019 Rs.	Year ended March 31, 2018 Rs.
Lincoln Parenteral Limited	Advance for Goods	2,13,50,000	Nil
Balances outstanding at each reporting date:			
Name of party	Nature of Amount	Year ended March 31, 2019 Rs.	Year ended March 31, 2018 Rs.
Lincoln Parenteral Limited Advance for Goods	Other current assets	2,13,50,000	Nil
Note: Figures in bracket denotes credit balance.			